The Research of Medical Science Review
ISSN: 3007-1208 & 3007-1216 Volume 3, Issue 4, 2025

NOVEL APPLICATIONS OF PROGRESSIVELY COMPLEX ARTIFICIAL ORGANS IN SURGICAL PRACTICE: AN INTEGRATIVE REVIEW OF ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES

Muhammad Moeed Azwar Bhatti*[1], Omer Farooq[2], Dr. Mamoon Ur Rasheed[3], Dr. Muslim Hassnain[4], Dr. Muhammad Hassan Asif[5], Dr. Shayan Shahid[6], Muhammad Matin[7], Rawal Hussain[8], Mahnoor Khan[9]

*[*1]Final Year MBBS Student HITEC IMS Taxila, Heavy Industry Taxila Educational Complex Institute of Medical Sciences (HITEC-IMS) Taxila*
[2]4TH Year MBBS Student HITEC IMS Taxila, Heavy Industry Taxila Educational Complex Institute of Medical Sciences (HITEC-IMS) Taxila
[3]Registrar orthopeadic, MBBS, Heavy Industry Taxila Educational Complex Institute of Medical Sciences (HITEC-IMS) Taxila
[4]Doctor, MBBS, Pak-Red Crescent Medical College & Hospital
[5,6]House-Officer, MBBS, Heavy Industry Taxila Educational Complex Institute of Medical Sciences (HITEC-IMS) Taxila
[7,8,9]Final Year MBBS Student, Muhammad Medical College

[*1]**azwarbhatti216@gmail.com**, [2]raoomerfarooq2@gmail.com, [3]mamoonurrasheed7@gmail.com, [4]muslimhasnain7@gmail.com, [5]hassanasif7676@gmail.com [6]docshaneshahid@gmail.com, [7]matinsheikh23@gmail.com, [8]rawalhussain796@gmail.com, [9]mahnoorkhaan786@gmail.com

DOI: https://doi.org/10.5281/zenodo.15187028

Keywords: *Artificial organs, bioengineering, organ transplantation, regenerative medicine, biocompatibility, surgical innovations, healthcare technology.*

Article History
Received on 02 March 2025
Accepted on 02 April 2025
Published on 10 April 2025

Corresponding Author: * Muhammad Moeed Azwar Bhatti*[1]

Abstract

Introduction: *Artificial organs have revolutionized modern medicine, providing life-saving alternatives for patients suffering from organ failure. The increasing prevalence of end-stage organ diseases, coupled with a shortage of organ donors, has driven significant advancements in artificial organ technology. These innovations aim to restore physiological functions and improve patient survival and quality of life. This review explores the progress, challenges, and future prospects of artificial organs in surgery.*

Historical Perspective: *The development of artificial organs dates back several decades, beginning with early mechanical heart valves and dialysis machines. Over time, technological advancements and biomedical engineering breakthroughs have led to the creation of more sophisticated devices, such as total artificial hearts and bioengineered tissues. Milestones in artificial organ development have paved the way for modern regenerative medicine approaches, including stem cell integration and tissue engineering.*

Current Advances: *Recent innovations in artificial organs have focused on improving biocompatibility, durability, and functional integration with the human body. Developments in cardiac support devices, bioartificial kidneys, pancreas, and liver assist systems have enhanced patient outcomes. Advances in biohybrid technologies and 3D bioprinting have further expanded possibilities for* *creating patient-specific artificial organs. Additionally, sensory organ prosthetics, such as artificial retinas and cochlear implants, have transformed the management of sensory deficits.*

Challenges and Limitations: *Despite significant progress, artificial organs face numerous challenges, including immune rejection, thrombogenicity, mechanical failure, and high costs. Ethical concerns regarding accessibility, long-term outcomes, and regulatory approvals further complicate their widespread adoption. Ensuring sustainability and affordability remains a pressing issue in artificial organ research and clinical application.*

Future Directions: *The future of artificial organs lies in the convergence of nanotechnology, regenerative medicine, and personalized healthcare. Stem cell-based therapies, organ-on-a-chip models, and AI-driven biofabrication hold promise for developing next-generation artificial organs with enhanced functionality and integration. Advancements in biomaterials and tissue engineering will further optimize long-term performance and patient compatibility.*

Conclusion*: Artificial organs represent a transformative field in modern surgery, bridging the gap between mechanical support and biological function. Continued research, ethical considerations, and policy frameworks are essential for overcoming current challenges and making artificial organ technology more accessible and effective. Future innovations will play a crucial role in addressing organ shortages and improving patient outcomes worldwide.*

INTRODUCTION

Artificial organs are one of the most revolutionary new technologies of the last century, providing life-saving solutions for patients with end-stage organ failure. Such devices, which can partially or fully replace the function of a failing organ, have gone from experimental prototypes to clinically viable options in recent decades.(1,2) Artificial hearts, biohybrid pancreas, biohybrid pancreas systems, and engineered kidneys are just some of the surgical innovations paving the way to a new horizon of surgical care for patients who may have never had a treatment option.(3–5)

The need for organ replacements has increased significantly over the past few years as the fast-growing population, along with the upsurge in chronic conditions, including diabetes and hypertension, keeps on increasing while the organ donor pool is not able to keep up with the same.(4,6) Millions of patients internationally are waiting for life-saving transplants, but according to the World Health Organization (WHO), the supply does not even cover a small percentage of the needs. This gap has propelled massive investments and research into artificial organs as a sustainable means of replacement transplantation.(7–9)

Artificial organs are promising artificial organs can provide long-term support to the organs facing irreversible damage while contributing to the field of regenerative medicine as well, however, multiple technical hurdles, ethical issues, and socio-economic factors limit the application of artificial organs. While devices such as ventricular assist devices (VADs), and wearable artificial kidneys have demonstrated potential, durability, biocompatibility, and costs remain formidable obstacles.(8–12) However, the implementation of artificial organs in standard clinical practice involves solving sophisticated regulatory and ethical problems, especially related to patient consent and access equity.

This narrative review aims to provide insight into the current role of this field in surgery in terms of recent advances, ongoing obstacles, and proposed future developments. To this end, this review offers an overview of how emerging leaders are changing the field of surgery and patient management through the lens of the technology facilitating this innovation, as well as the potential barriers to clinical use and implementation. This discussion will highlight the potential of artificial organs to expand the current organ shortage and improve the quality of life for end-stage organ failure patients.

Historical Perspective

The search for artificial substitutes for human organs is as old as medicine, founded on humanity's ancient desire to transcend biological limits.(13,14) Early efforts were rudimentary but forward-looking: in the 3rd century BCE, Greek doctors pumped hollow reeds into swollen organs to drain fluid, foreshadowing modern-day drainage systems. The real dawn of artificial organ use arrived in the 20th century, however, driven by war-time innovation as well as advances in surgery, engineering , and materials science coming together.(13,14)

The heart-lung machine, invented by John Gibbon in 1953, was revolutionary. By replacing cardiopulmonary function during open heart surgery for a short period, it proved that not only could machines perform tasks in the human body, but that necessary organ systems could also be mimicked — something which had been limited to the realm of science fiction.(15–17) This was the foundation for more ambitious projects, such as the first implantable artificial heart. In 1982, the Jarvik-7, a pneumatic device, was implanted in Barney Clark, who survived for 112 days. This milestone was fraught with complications but ignited worldwide interest in mechanically replacing a man's organs.(17–19)

Similar strides were made in renal care. Willem Kolff, who is hailed as the father of artificial organs, invented the rotating drum kidney in 1943, one of the precursors to modern hemodialysis machines.(20–23) By the 1960s, dialysis had evolved from an experimental therapy to a life-sustaining standard, with millions surviving end-stage renal disease. Likewise, the ventricular assist device (VAD), which was first used clinically in the 1960s, was adapted over the decades from the bulky, infection-prone systems to today's more compact, implantable pumps, such as the HeartMate 3, that can keep patients alive for years, either as a bridge to transplant or destination therapy.(12,21–23)

Artificial organs are no longer limited to life support; the late 20th century saw them moving to functional restoration. The cochlear implant, which received FDA approval in 1984, became the first device to successfully link with the nervous system, restoring hearing to the profoundly deaf.(24,25) The artificial pancreas, which emerged in the 2000s, combined continuous glucose monitoring with insulin delivery to revolutionize diabetes care.(1,2,6,26,27)

Much of the 21st century so far has been the age of biohybrid systems and bioengineered organs. With innovations like 3D-printed tracheal scaffolds (2011) and machine-perfused "living" kidneys (2020s), the synthetic and biological become intertwined in blurring distinction. These advances represent a paradigm shift: artificial organs are not simply substitutes, but platforms for regeneration and personalized medicine.(4,28,29)

Types of Artificial Organs

Artificial organs encompass a wide range of technologies, each designed to meet the specific physiological requirements of failing organ systems. These range from mechanical substitutes that provide access to basic functions to biohybrids that seamlessly interface living cells with synthetic electrodes. Here, we cover the most important types of artificial organs, their clinical uses, and their game-changing roles in contemporary surgery.

Cardiac Artificial Organs

Cardiac failure continues to be among the top causes of worldwide mortality and thus spurred advances in mechanical circulatory support.(19) Total artificial hearts (TAHs), such as the SynCardia Temporary Total Artificial Heart, are used as bridge-to-transplant devices and substitute both ventricles and valves in biventricular failure patients.(15,17,30) Second-generation designs, such as the CARMAT bioprosthetic heart, which integrates biosensors and biological materials to minimize clotting risk, are designed for chronic use. The advent of ventricular assist devices (VADs), such as the HeartMate 3 and HVAD, has transformed the management of patients with a single failing ventricle. These implantable pumps now provide destination therapy for nontransplantation candidates with increased durability and hemocompatibility.(12,15,31)

Renal Replacement Systems

Chronic kidney disease (CKD) is a global epidemic that impacts > 850 million people worldwide and drives the need for advancements in renal support. Traditional hemodialysis machines are lifesaving, yet they are inherently limited by nature — stationary and only used intermittently. Innovations such as the Wearable Artificial Kidney (WAK), a miniaturized device that is currently being evaluated in clinical trials, hold the potential for continuous dialysis that allows patients more movement.(20,32,33) Meanwhile, bioartificial kidneys, like the University of California San Francisco's implantable model, bring together synthetic membranes with living kidney cells to mimic filtration and metabolic functions — an option that may help solve the organ shortage in the long run.(20,32,33)

Pancreatic Devices

Medical devices have been revolutionized by the artificial pancreas, a closed-loop system that combines continuous glucose monitors (CGMs) with insulin pumps, facilitating diabetes management. Devices such as the Medtronic MiniMed 780G autonomously adapt insulin delivery and closely mimic the function of pancreatic β-cells.(34) Novel biohybrid technologies like the ViaCyte PEC-Direct encapsulate stem cell-derived islet cells in semi-permeable membranes, combining both mechanical and biological methods of insulin regulation.(35–37)

Hepatic Support Technologies

Acute liver failure requires prompt treatment, but donor livers are limited. Bioartificial liver support systems (BLSS) such as the ELAD ® (Extracorporeal Liver Assist Device) employ hollow-fiber bioreactors charged with human hepatocytes for detoxification of blood and synthesis of proteins. Though still experimental, BLSS has been shown to be a viable means of bridging patients to transplantation.(38–41) Molecular adsorbent recirculating systems (MARS) similarly use albumin dialysis to remove toxins—offering short-term support to those with liver failure.(42)

Pulmonary Assist Devices

Extracorporeal membrane oxygenation (ECMO) — the practice of oxygenating blood outside the body — has transformed critical care, providing an alternative for patients with severe, dysfunctional lungs or hearts.(43–45) Recent advances in miniaturization, including the Hemolung Respiratory Assist System, offer the opportunity for prolonged ambulatory use.(46–48) Meanwhile, in the search for implantable artificial lungs — the University of Pittsburgh's — PARC device promises compact, biocompatible, long-term respiratory support.(49–51)

Sensory Organ Prosthetics

Synthetic organs have restored sensory functions once believed to be irretrievable. Cochlear implants, which received F.D.A. approval in 1984, bypass damaged hair cells, stimulating the auditory nerve directly, allowing profoundly deaf people to hear.(25,52,53) They convert visual stimulation into electric energy applied to the provided retinal prosthesis (e.g., Argus II) in retinal degeneration patients. Recent innovations in optical nerve interfaces and cortical implants suggest technologies that can make blind people see, even in the case of total ocular clusters.(54–56)

Technological Advancements

The fast progress of artificial organs is being supported by high-end innovations in materials science, additive manufacturing, bioengineering, and artificial intelligence. Such advances go beyond improving device performance to transforming what artificial organs can do, moving from mimicking biological functions toward enabling regeneration and autonomy. We will examine some of the main technological factors accelerating this field below.

Materials Science: The Middle Ground of Living and Non-living

Materials science has been transformed by the race to achieve seamless integration of artificial devices and human tissues. Now, biocompatible polymers like polyurethane and silicone are the materials of choice for implantable devices; they minimize inflammatory activation and thrombogenicity.(57) Nanotechnology-coated surfaces, for example, graphene-based electrodes in neural implants, result in better signal transduction and less scar tissue formation. At the same time, they are enabling dynamic bio-integration based on external stimulation from, for instance, selfhealing hydrogels, or smart materials that respond to physiological cues, like pH or temperature.(46,47) The Carmat artificial heart, for example, is built on bovine pericardial tissue fixed with proprietary polymers — a compromise between durability and biological compatibility.(58–60)

Customization at Scale with 3D Printing

Those types of specifications Together with additive manufacturing, have opened up the method that could design tailored artificial organs with an incredible degree of precision. Bioink loaded with living cells techniques like bioprinting enables the creation of scaffolds specific to the patient for cartilage, blood vessels, and cardiac patches. In 2019, Tel Aviv University researchers introduced the first human 3D-printed heart with human cells and vasculature, a breakthrough for paved the way for personalized organ manufacturing.(61–63) In addition to biopharmaceuticals, 3D printing also allows for intricate geometries with respect to mechanical organs, for example, lightweight titanium parts for VADs.(62–64) Individualized anatomy is the driving force for mind-of-the-art tracheal stents and cranial implants that are in clinical use to diminish rejection and surgical complications.

Understanding biohybrid Systems: The Combination of Synthetic and Living Components

Biohybrid artificial organs combine synthetic materials and living cells, resulting in systems that utilize the best features of each. Emulate Bio's Liver Chip, for instance, encapsulates human hepatocytes within a microfluidic platform to simulate liver metabolism used for drug testing.(51) In one specific clinical application, devices such as the Bioartificial Pancreas use semi-permeable membranes to entrap cells that secrete insulin (islet cells) and provide an immune-protective environment while permitting a glucose-responsive release of insulin. Likewise, decellularized organ scaffolds, on which native cells are stripped and repopulated with patient-derived stem cells, are being studied for kidney and lung regeneration. These systems challenge the distinction between transplantation and mechanical replacement and open up possibilities toward true biological integration.

AI and Machine Learning: Becoming Adaptive Smart Organs

AI is bringing interactivity to inert devices, turning them into independent systems — people even call them passive intelligence.(11,65,66) The Tandem Control-IQ is a closed-loop artificial pancreas that uses machine learning algorithms to predict glucose trends and provide dynamic insulin delivery.(67,68) In the field of cardiac care, both deep learning and machine learning-powered VADs facilitate dynamic optimization of the pump speed by leveraging patient's physiological signals to enhance hemodynamic stability.(46,47) Removed from patient-specific control, AI also speeds up organ design: neural networks can scour vast datasets for clues on how to devise new biomaterials or simulate the fickle dance of fluid dynamics in artificial lungs.(47,49–51) Prellis Biologics and other startups use AI to map vascular networks for 3D-printed organs so that nutrients are delivered most efficiently. These technologies usher in an era of "smart" organs that can learn, adapt, and evolve with their users.

Impact on Surgical Practice

These innovations are transforming surgical processes and patient treatment. Surgeons now work with engineers to design 3D-printed organ implants ahead of surgery, and AI-powered devices decrease postoperative monitoring requirements.(65,69,70) Still, experimental but promising biohybrid systems would dwarf lifelong immunosuppression associated with transplant-like therapies. As these technologies mature, they will blur even further the roles of surgeon, engineer, and biologist — ushering in an era of truly interdisciplinary medicine.(8,65,71,72)

Clinical Applications

Artificial organs have evolved from experimental curiosities to essential items in modern surgical practice, meeting a range of clinical needs from sustaining life in critical crises to restoring autonomy in chronic disease. There are three general areas of application: bridging patients to transplantation, delivering permanent therapeutic solutions, and augmenting rehabilitation and quality of life. We now look at these roles through the lens of real-world impact and patient outcomes.

Bridge to Transplant: Lengthening Life Through Critical Windows

In patients with transplant waitlists, artificial organs act as critical lifelines, salvaging dysregulating organ function until a matched organ is available. Extracorporeal membrane oxygenation (ECMO), for example, offers short-term cardiopulmonary support to those with acute heart or lung failure and can half waitlist mortality among eligible candidates.(44,45) Ventricular assist devices (VADs) such as the HeartMate 3 are now standard in the care of patients with advanced heart failure, with data demonstrating 80% survival to transplant.(12,60)

Innovations have opened up bridging possibilities beyond established parameters. The SynCardia Total Artificial Heart (TAH) has extended survival in patients with bi-ventricular failure with some recipients living over 1000 days on the device.(73–75) Some non-invasive systems are designed for the patient to wait at home for transplantation and have been shown to increase psychological well-being and decrease hospital expenses (e.g., the Freedom® Driver for use with the SynCardia TAH).(76,77) The development of miniaturized ECMO circuits and Berlin Heart EXCOR® pediatric VADs in neonatal care have significantly improved our outcomes in infants with congenital heart defects; the same is true of most bridging technologies—their scalability.(43–45)

Destination Therapy: Permanent Solutions to Complicated Problems

For patients who do not wish to undergo transplantation—or who face age or comorbidity barriers, or an immunological barrier—artificial organs offer a long-term or permanent solution. Long-term use of left ventricular assist devices (LVADs), once restricted to temporary use, now allows for durable support as destination therapy, with 5-year survival rates of ≥60%. The HeartMate 3's magnetically levitated rotor has decreased complications such as pump thrombosis and has allowed decades of use in select patients.(6,12,48,50)

WAKs and implantable bioartificial systems in renal care strive to decouple patients from dialysis centers. The WAK is a wearable device prototype, clinically tested, that provides continuous ambulatory dialysis, mimicking the natural kidney function more than intermittent hemodialysis.(9,20,28,32) Regarding diabetes, the artificial pancreas made its way out of the specialty corner and into the mainstream, with the Omnipod 5® representing one of the first systems to provide automated glucose control, which reduces hypoglycemic episodes by 75% in trials.(35,36,75)

These technologies are especially game-changing in resource-poor environments, in which donor organs are in short supply. Portable dialysis systems and solar-powered VADs are being piloted in sub-Saharan Africa to combat the double burden of end-stage organ disease and infrastructure shortfalls.

Rehabilitation and Quality of Life: The Survivorship Issue

The focus on artificial organs is increasingly aimed not only at longer lives but at normalcy too. Cochlear implants have restored auditory function to more than 1 million deaf people around the world, and pediatric recipients often develop speech comparable to that of their hearing peers. In much the same way, retinal prostheses such as the Argus II bring some vision back to patients; they can navigate their environments themselves, which is a huge change from being completely blind.(2,6,26)

The combination of artificial organs with digital health tools will help in the management of chronic diseases where patients are empowered. Smart artificial pancreas, for instance, interfaces with smartphone apps so that diabetics can receive real-time trends in glucose levels, dietary advice, and remote monitoring. At the same time, neuro prosthetics (including brain-computer interfaces, or BCIs, for limb control) are revolutionizing the rehabilitation of patients with spinal cord injury.(30,35)

The psychosocial benefits are significant as well. According to studies of VAD recipients, improved mental health and greater engagement with society are observed because of reduced symptom burden and regained functional mobility. By reducing dependency on a hospital for care, wearable technology also lessens the stigma and loneliness often accompanying chronic illness.

Challenges and Limitations

Artificial organs are considered to have transformative potential, but the path to development and implementation is fraught with challenges on many fronts. These barriers cut across technical, biological, ethical, regulatory, and socioeconomic domains, and will need interdisciplinary collaboration to overcome. Here, we break down the key limitations that hamper the field today.

Beast Mode: The Technical Problems of Engineering

Artificial organs should endure ceaseless physiological stresses, and also be accurate. Durability still is a major challenge: rotating mechanical components, such as pump rotors in congenital ventricular assist devices (VADs), fail because of friction and material fatigue.(7,78,79) Early VAD models, for example, had to be replaced regularly while new technologies, such as the HeartMate 3's magnetically levitated rotor, have increased the lifespan to 10+ years. Energy supply is another bottleneck: implantable devices depend on external batteries or transcutaneous energy transfer systems (TETS) that risk infection and impair mobility. Wireless charging and biocompatible fuel cell innovations are fledgling but promising. Miniaturization is also an important factor, especially in the case of pediatric patients. There are adult-size artificial hearts, such as the Carmat, but no one knows how to scale them to infants without giving up efficiency.(58,59)

Debugging the Microbiome: A Biological Challenge

Although biocompatibility has improved, artificial organs elicit multiple adverse responses from the host. While material-tissue interfaces are immune-privileged, they are still marked by chronic inflammation and immune rejection, though less than in transplants. For instance, biofilm development on dialysis catheters or VAD drivelines increases susceptibility to infection, with sepsis diagnosed in 20–30% of long-term VAD patients.(70,80) Furthermore, sensitive infectious pathogens are becoming more resistant to antibiotics, greatly complicating the use of antibiotics when treating severe infections. Indeed, long-term VAD and dialysis patients exhibit a spectrum of colonic dysbiosis associated with the gradual loss of microbial diversity and the overgrowth of enterobacteria, where the alteration of the gut inflammation–microbiota–barrier axis results in increased susceptibility to infection, and opinionated colonization by multidrug-resistant enterobacteria can potentially engender acute kidney injury injury.(13,80,81) Gut dysbiosis has also been implicated in hypertension and the development of heart failure in animal models and in clinical trials, where the effects of gut microbiota modulation have been documented in mouse models of hypertension.(7,8,82) These factors necessitate the provision of effective antibiotic therapy for seriously infected patients and the decision regarding the administration of broad-spectrum antibiotics. However, the continued use of certain antibiotics over the years can generate drug-resistant enterobacteria.(7,8,29) We postulate that the various changes in gut microbiota and gut dysbiosis correlate with the gradual loss of integrity of the intestinal barrier and the increase in intestinal permeability. Biocompatibility challenges also affect thrombosis: in-dwelling synthetic surfaces such as titanium or polyurethane can activate blood clotting cascades requiring lifelong anticoagulation with inherent risks of bleeding. Biohybrids have to overcome further challenges, including the survival and function of encapsulated cells, e.g. in the case of the BioArtificial Pancreas.(9,10,82–84)

Ethical Challenges: The Tug-of-War Between Innovation and Responsibility

The emergence of artificial organs poses deep ethical dilemmas. Then there is the informed consent challenge with experimental therapies, which patients who are close to death may overestimate the benefits of. Another issue is equity of access: advanced devices such as the Carmat heart (more than $200,000) are largely available only in high-income countries, increasing global health disparities.(7,58,59) Moreover, the definition of "life" involving artificial organs is controversial. For example, certain patients with prolonged ECMO or total artificial hearts can survive without a realistic chance of recovery, forcing the clinician into a dynamic tension between hope and futility.(43–45) Synthetic implants for gender-affirming surgeries face a similar societal and cultural bias, highlighting the need for inclusive ethical paradigms.

Challenges Ahead: Complexities of the Regulatory Landscape

Due to their hybrid mechanical-biological nature, artificial organs are inherently complex to obtain regulatory approval for. The FDA's Premarket Approval (PMA) process, which demands mountains of preclinical and clinical testing, can hold up life-saving technologies for decades. For example, the Wearable Artificial Kidney (WAK) 15 years later is still in trials. So is long-term safety monitoring: post-market surveillance generally cannot detect rare complications that occur, such as late-stage device failures in destination therapy VADs. Internationally, diverging standards—like the EU's CE marking compared to U.S. FDA pathways—add yet more layers of complexity and layers of frustration for commercialization and adoption.(7,8,82–84)

Socioeconomic Divide: The Cost and Accessibility

Artificial organs are some of the most expensive medical technologies, with R&D, materials, and regulatory compliance all driving costs up. An ECMO circuit can cost up to \$50,000–\$100,000, whereas lifelong expenses for VAD patients already surpass \$1 million.(7,78,81) Such therapies become inaccessible in low-resource settings, where 90% of the global population does not have access to safe and affordable surgery. Disparities are even more pronounced within affluent countries: marginalized communities have some portion of mortality due to insufficiencies in insurance coverage and biases in treatment by the system. Black patients in the U.S., for instance, are 30% less likely than white patients to receive VADs, an effect seen in wider access inequities.(65,70,79)

Systematic Approach: A Call for Systems Thinking

These challenges do not exist in silos but are deeply interdependent. These high costs worsen ethical inequities and technical limitations amplify the biological risks. For example, miniaturized pediatric devices require expensive precision engineering, which in turn restricts access. Similar advancements in biocompatibility (i.e., heparin-coated circuits) have increased the costs of production, posing challenges between biocompatibility, safety, and affordability.

Progress and Pathways Forward

Efforts are being made to address these barriers. These technical solutions include: graphene-based batteries that can make implants last longer and 3D-printed organs made with cells derived from the patient's own body which can reduce organ rejection. Policy efforts, such as the WHO's (World Health Organization) Global Surgery Initiative, seek to increase access with investment and training. At the same time, ethical guidelines like the Montreal Declaration on Sustainability in Surgery call for sustainable, equitable innovation.

Future Directions

Artificial organs have the potential to change the course of surgery, bringing together the latest technology with a focus on the individual patient. As the field develops and matures, five key directions—personalization, regenerative integration, device portability, global equity, and ethical governance—will guide the next frontier of human-computer interaction (HCI). These pathways not only seek to surpass existing limitations but also reconceptualize the parameters of what artificial organs may facilitate.

Precision-based Personalised Artificial Organs

The days of blanket devices are behind us. The pressing need for personalized tissue and organ grafts will be addressed through 3D bioprinting, multi-omics profiling, and AI-enabled predictive modeling, paving the way for organs customized to individual anatomies, immune phenotypes, and lifestyles.(85,86) The researchers at Carnegie Mellon University, for example, are developing patient-specific cardiac patches with the joint help of printed collagen and stem cells to heal congenital heart defects. Likewise, organ-on-chip systems, personalized with a patient's cells, could function as "test beds" to optimize device compatibility before implantation. Startups like Pandorum Technologies have already begun printing personalized corneal tissues, suggesting that in too distant future getting bespoke organs could become the norm.(86)

Regenerative Medicine Integration: Offering Healing of the Healing Replacement

Next-generation artificial organs will synergize progressively with regenerative therapies to stimulate endogenous repair. For example, biohybrid systems, including the stem cell-derived islet-encapsulating bioartificial pancreas, are designed to restore native organ function in an immunoisolating environment with a reduced need for immunosuppression.(87) Trials of decellularized lung scaffolds repopulated with patient cells (e.g., the BREATH Lung Project) are showing potential in reversing pulmonary fibrosis. And electroceutical devices — implants that use electrical cues to stimulate tissue regeneration — are under trial to regrow nerves and bone. The end goal: ephemeral artificial organs that dissolve as the body heals itself.(88–90)

The Invisible Nature of Care — Wearable and Implantable Devices

Future devices will be focused on not getting in the way and self-dependence. For example, flexible electronics and soft robotics are driving skin-adherent artificial kidneys and beneath-the-skin glucose sensors that seamlessly integrate with everyday life. The Nano Artificial Pancreas, an under-development, coin-sized implant, uses graphene-based sensors to monitor and deliver insulin without the use of external pumps.(13,91) Energy problems are being solved with innovations like biothermal batteries (harvesting body heat) and ultrasonic wireless charging. For pulmonary assistance, MIT's Ambulatory Artificial Lung prototype, which the patient wears like a stylish vest, enables users to retain active lifestyles while their bodies receive continuous oxygenation.(5,85,92)

Part I: Democratizing Access — Global Impact

To close the artificial organ gap between high- and low-income regions, frugal innovation and system collaboration are needed. Initiatives such as Project Daniel, which utilizes 3D printing to produce prosthetic limbs in war-ravaged regions, provide a template for decentralized production of less complicated devices. In sub-Saharan Africa, partnerships between NGOs (such as Mercy Ships) and academia are trialing solar-powered dialysis units. In the meantime, telemedicine platforms such as Telesurgery Africa are training local teams to keep machines in working order and troubleshoot remotely. The WHO's Global Initiative for Essential Surgical Care promotes tiered pricing models to increase access to technologies, such as VADs, in low-resource settings.

Ethical and Policy Frameworks: Fostering Responsible Innovation

As artificial organs fuse humans and machines, good governance is imperative. Key priorities include:

- AI Transparency: Standards for clear expectations on accurate information from AI-driven devices (e.g., neural implants)
- EquityMetrics: Organizations mandating affordability clauses for R&D funding (NIH's REMEDY Program, etc.)
- Cultural Competence: Designing devices for marginalized communities (e.g., patient shelling with transgender patients to come up with gender-affirming prosthetics).
- Permanent Devices EOL Guidelines: termination of permanent implants in terminally ill patients

The Montreal Declaration on Sustainability in Surgery (2023) and the WHO's Global Guidelines for AI in Health (2024) provide nascent frameworks,1 but the adoption of binding international treaties will be necessary to achieve standards harmonization.

Converging Visions: The Path Forward

These trajectories define the future of artificial organs. Now, consider a diabetic patient living in rural India wearing a nano patch artificial pancreas that operates on body heat while their frequent insulin injections are replaced with a biohybrid implant that regenerates islet function. Or a Syrian refugee who receives a 3D-printed trachea at a field hospital, and follow-up care through blockchain-secured telemedicine. Realizing such scenarios takes more than innovation — it requires breaking down silos between engineers and nurses, surgeons, policymakers, and communities.

Conclusion

Once a staple of speculative science fiction, artificial organs have already become cornerstones of modern surgical practice — life-saving interventions for millions of patients around the world. The developments made and avenues forged in the past have led to what is sought in today's world — biohybrid systems that synthesize the specificity of the synthetic with the complexity of the biological, devices powered by artificial intelligence, capable of adaptive self-regulation, as well as 3D-printed organs matched to the anatomy of individual patients. Technologies such as the Carmat bioprosthetic heart, wearable artificial kidneys, and closed-loop artificial pancreas illustrate the field's evolution, bridging the gap between the supply of organs and the demand while transforming rehabilitation and quality of life.

But artificial organs have the power to transform lives beyond replacing failed, worn-out systems. These technologies will democratize perioperative care access, empower patients through wearables and telemedicine integrations, and initiate a shift from reactive treatment to proactive regeneration. The cross-pollination of regenerative medicine, nanotechnology, and machine learning offers a tantalizing peek at a future in which artificial organs do not merely prolong life, but restore it — dissolving after their biological counterparts heal, or evolving with the body as its needs change.

But this vision will require overcoming long-standing obstacles. Technical hurdles such as energy efficiency and biocompatibility require advances in materials science and robotics. The ethical questions arising, from fair access to the philosophical impact of humans merging with machines demand inclusive, globally uniform frameworks. These socioeconomic disparities reinforce the need for systemic reforms in healthcare financing and education, to counteract prohibitive costs and infrastructural gaps.

To achieve these will require unprecedented interdisciplinary partnerships. Surgeons need to collaborate with engineers to improve device design, with policymakers to ensure equitable regulations, and with communities to make sure that innovation is culturally competent. The WHO's Global Surgery 2030, and the Montreal Declaration on Sustainability in Surgery provide blueprints to optimize the practice of surgery, but both require a collective commitment to achieve their objectives.

All in all, artificial organs are more than a technical success — they are the triumphant culmination of the centuries-old goal of medicine to face death with ingenuity and care. By coupling technical genius with moral guardianship, the global surgical community can guarantee that these technologies fulfill their highest calling: not simply prolonging life but reinvigorating it.

Authors Contribution

[*1]Conceptualization, study design, manuscript drafting, reviewing, editing, supervision, final approval, accountability

[2]Drafting, study design, manuscript writing, proofreading, critical revisions, final approval, accountability.

[3,4,5,6,8]Drafting writing significant sections of the manuscript, critical revisions, consistency check, final approval, accountability.

[7,9]Conclusion writing, proofreading, manuscript preparation, critical revisions, final approval, accountability

REFERENCES

1. Vanholder R, Ringoir S. Artificial organs--an overview. Int J Artif Organs. 1991;14(10):613–8.
2. Gurland HJ, Mujais SK. The future of artificial organs. International Journal of Artificial Organs. 1995 Feb;18(2):64–8.
3. Zhang Y, Yu W, Lv G, Zhu J, Wang W, Ma X, et al. The Artificial Organ: Cell Encapsulation. Comprehensive Biotechnology, Second Edition. 2011 Sep 9;5:99–114.
4. Stewart-Clark S, Wen X. Artificial Organs: Kidney. Comprehensive Biotechnology, Second Edition. 2011 Sep 9;5:685–98.
5. Remuzzi A. Artificial organs: Current status and future directions. International Journal of Artificial Organs. 2016 Dec 1;39(12):587–9.
6. Jones JR. Artificial organs. Biomaterials, Artificial Organs and Tissue Engineering. 2005;142–52.
7. Sohn S, Van Buskirk M, Buckenmeyer MJ, Londono R, Faulk D. Whole Organ Engineering: Approaches, Challenges, and Future Directions. Applied Sciences (Switzerland). 2020 Jun 1;10(12).
8. Lee H, Neville K. The Challenge for High Polymers in Medicine, Surgery, and Artificial Internal Organs. Journal of Macromolecular Science: Part A - Chemistry. 1970;4(3):757–73.

9. Karageorgos FF, Neiros S, Karakasi KE, Vasileiadou S, Katsanos G, Antoniadis N, et al. Artificial kidney: Challenges and opportunities. World J Transplant. 2024 Mar 18;14(1).
10. Welman T, Michel S, Segaren N, Shanmugarajah K. Bioengineering for organ transplantation: Progress and challenges. Bioengineered. 2015;6(5):257–61.
11. Bhatti H, Moeed Azwar Bhatti M, Ali M, Shahid S, Javed M, Ali S, et al. AUGMENTED AND VIRTUAL REALITY IN RADIOLOGY: A COMPARATIVE ANALYSIS OF CLINICAL APPLICATIONS AND OUTCOMES. Journal of Medical & Health Sciences Review [Internet]. 2025 Mar 18 [cited 2025 Mar 31];2(1). Available from: https://jmhsr.com/index.php/jmhsr/article/view/159
12. Pirk J, Maly J, Szarszoi O, Urban M, Kotulak T, Riha H, et al. Total artificial heart support with two continuous-flow ventricular assist devices in a patient with an infiltrating cardiac sarcoma. ASAIO Journal. 2013 Mar;59(2):178–80.
13. Hu K, Li Y, Ke Z, Yang H, Lu C, Li Y, et al. History, progress and future challenges of artificial blood vessels: a narrative review. Biomaterials Translational. 2022 Mar 1;3(1):81–98.
14. Ash SR. Artificial organs: A new chapter in medical history. ASAIO Journal. 2006;52(6).
15. Jaron D. Current status of the artificial heart and cardiovascular assist devices. Proceedings of the 1990 IEEE Colloquium in South America, COLLOQ 1990. 1990;3–6.
16. Mertz L. From artificial kidneys to artificial hearts and beyond: New developments offer great hope. IEEE Pulse. 2012;3(3):14–20.
17. Gerosa G, Scuri S, Iop L, Torregrossa G. Present and future perspectives on total artificial hearts. Ann Cardiothorac Surg [Internet]. 2014 Nov [cited 2025 Mar 29];3(6):595–602. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25512901
18. Donato L, Mambrito B. The artificial heart: Device and concept evolution. Technology and Health Care. 1996;4(1):37–41.
19. Trumble DR. Artificial Hearts and Cardiac Assist Devices: Performance, Control, and Power Delivery. Wiley Encyclopedia of Electrical and Electronics Engineering. 2016 Nov 15;1–10.
20. Dominy CL, Shamsian EB, Okhawere KE, Korn TG, Meilika K, Badani K. Recent innovations in renal replacement technology and potential applications to transplantation and dialysis patients: A review of current methods. Kidney Res Clin Pract. 2023 Jan 1;42(1):53–62.
21. Kolff WJ. PRESENT STATUS OF ARTIFICIAL INTERNAL ORGANS. Ann N Y Acad Sci. 1964;120(1):535–9.
22. Kolff WJ. Exponential Growth and Future of Artificial Organs. Artif Organs. 1977;1(1):8–18.
23. Kolff WJ. Old, new and revised aspects of artificial organs. International Journal of Artificial Organs. 1980;3(2):94–102.
24. Zeng FG. Trends in Cochlear Implants. Trends Amplif. 2004;8(1):1–34.
25. Eshraghi AA, Nazarian R, Telischi FF, Rajguru SM, Truy E, Gupta C. The Cochlear Implant: Historical Aspects and Future Prospects. Anatomical Record. 2012 Nov;295(11):1967–80.
26. Malchesky PS. Artificial organs and vanishing boundaries. Artif Organs. 2001;25(2):75–88.
27. Bronzino JD. Tissue engineering and artificial organs. Tissue Engineering and Artificial Organs. 2016 Apr 19;1–1304.
28. Artificial Kidney, Artificial Liver, and Artificial Cells. Artificial Kidney, Artificial Liver, and Artificial Cells. 1978;
29. Di Paola L. Artificial kidney: A chemical engineering challenge. Current Trends and Future Developments on (Bio-) Membranes: Membrane Applications in Artificial Organs and Tissue Engineering. 2020 Jan 1;1–20.

30. Hanzelka P, VaŠkå J, Urbdáek P, VaŠkå J, Urbánek E. Artificial Organs: Thoughts & Progress:Determination of Cardiac Output of the Artificial Heart from the Drive Air Flow. Artif Organs. 1979;3(3):277–8.
31. Tarcan B. Unveiling the future of cardiac care: advances in mechanical circulatory support. Journal of Mechatronics and Artificial Intelligence in Engineering. 2024 Jun 30;5(1):115–30.
32. Attanasio C, Latancia MT, Otterbein LE, Netti PA. Update on Renal Replacement Therapy: Implantable Artificial Devices and Bioengineered Organs. Tissue Eng Part B Rev. 2016 Aug 1;22(4):330–40.
33. Pantakitcharoenkul J, Coblyn M, Jovanovic G. Extracorporeal Blood Therapeutic Devices for Renal Replacement: A Review of Current Technologies and Future Directions Toward Microscale-based Devices. Chem Biochem Eng Q. 2023;37(4):189–201.
34. Passanisi S, Lombardo F, Mameli C, Bombaci B, Macedoni M, Zuccotti G, et al. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780GTM in Children, Adolescents and Young Adults: A Systematic Review. Diabetes Therapy. 2024 Feb 1;15(2):343–65.
35. Sambanis A. Artificial Organs | Pancreas. Comprehensive Biotechnology, Second Edition. 2011 Sep 9;5:699–711.
36. Boughton CK, Hovorka R. Advances in artificial pancreas systems. Sci Transl Med. 2019;11(484).
37. Philippidis A. Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes. GEN Edge. 2022 Jan 1;4(1):169–75.
38. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix Extracorporeal Liver Assist Device: Initial Clinical Experience. Artif Organs. 1994;18(5):390–6.
39. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996 Dec;24(6):1446–51.
40. Rozga J, Demetriou AA. Development and testing of a bioartificial liver. The Hepatocyte Review. 2000;543–59.
41. Lee KCL, Stadlbauer V, Jalan R. Extracorporeal liver support devices for listed patients. Liver Transplantation. 2016 Jun 1;22(6):839–48.
42. SINGAPORE HTAAOM, 2004 undefined. Molecular adsorbent recirculating system (MARS). annals.edu.sg [Internet]. 2004 [cited 2025 Apr 1];33(3). Available from: https://www.annals.edu.sg/pdf200405/V33N3p329.pdf?itool=Abstract&db=pubmed&uid=15175774&PrId=4981&url=http://www.annals.edu.sg%2Fpdf200405%2FV33N3p329.pdf&nlmid=7503289
43. Langer T, Santini A, Bottino N, Crotti S, Batchinsky AI, Pesenti A, et al. "Awake" extracorporeal membrane oxygenation (ECMO): Pathophysiology, technical considerations, and clinical pioneering. Crit Care. 2016 Jun 30;20(1).
44. Mosier JM, Kelsey M, Raz Y, Gunnerson KJ, Meyer R, Hypes CD, et al. Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: History, current applications, and future directions. Crit Care. 2015 Dec 17;19(1).
45. Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology. Crit Care. 2016 Nov 28;20(1).
46. Akkanti B, Jagpal S, … RDCC, 2021 undefined. Physiologic improvement in respiratory acidosis using extracorporeal Co2 removal with hemolung respiratory assist system in the management of severe respiratory. journals.lww.com [Internet]. [cited 2025 Apr 1]; Available from: https://journals.lww.com/ccejournal/fulltext/2021/03000/physiologic_improvement_in_respiratory_acidosis.11.aspx.

47. Saavedra-Romero R, Paz F, Litell JM, Weinkauf J, Benson CC, Tindell L, et al. Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System. Case Rep Crit Care. 2021;2021.
48. Jeffries RG, Mussin Y, Bulanin DS, Lund LW, Kocyildirim E, Zhumadilov ZZ, et al. Pre-clinical evaluation of an adult extracorporeal carbon dioxide removal system with active mixing for pediatric respiratory support. International Journal of Artificial Organs. 2014;37(12):888–99.
49. Swol J, Shigemura N, Ichiba S, Steinseifer U, Anraku M, Lorusso R. Artificial lungs--Where are we going with the lung replacement therapy? Artif Organs. 2020 Nov 1;44(11):1135–49.
50. Ota K. Advances in artificial lungs. Journal of Artificial Organs. 2010 Apr;13(1):13–6.
51. Sawa Y, Ohata T, Takagi M, Suhara H, Matsuda H. Development of hybrid artificial lung with gene transfected biological cells. Journal of Artificial Organs. 2000;3(1):1–4.
52. Deep NL, Dowling EM, Jethanamest D, Carlson ML. Cochlear Implantation: An Overview. J Neurol Surg B Skull Base. 2019;80(2):169–77.
53. House WF, Berliner K, Crary W. Cochlear implants. Annals of Otology, Rhinology and Laryngology. 1976;85(3 II,SUP27).
54. Stronks HC, Dagnelie G. The functional performance of the Argus II retinal prosthesis. Expert Rev Med Devices. 2014 Jan;11(1):23–30.
55. Farvardin M, Afarid M, Attarzadeh A, Johari MK, Mehryar M, Hossein Nowroozzadeh M, et al. The Argus-II retinal prosthesis implantation; From the global to local successful experience. Front Neurosci. 2018 Sep 5;12(SEP).
56. Dagnelie G, Christopher P, Arditi A, da Cruz L, Duncan JL, Ho AC, et al. Performance of real-world functional vision tasks by blind subjects improves after implantation with the Argus® II retinal prosthesis system. Clin Exp Ophthalmol. 2017 Mar 1;45(2):152–9.
57. Treasure T. Recent advances. Cardiac surgery. Br Med J. 1997;315(7100):104–7.
58. Mohacsi P, Cardio-Thoracic PLEJ of, 2014 undefined. The CARMAT total artificial heart. academic.oup.com [Internet]. [cited 2025 Apr 1]; Available from: https://academic.oup.com/ejcts/article-abstract/46/6/933/2755263
59. Guyonnet L, Detriché G, Gendron N, Philippe A, Latremouille C, Soret L, et al. Elevated Circulating Stem Cells Level is Observed One Month After Implantation of Carmat Bioprosthetic Total Artificial Heart. Stem Cell Rev Rep. 2021 Dec 1;17(6):2332–7.
60. Huenges K, Panholzer B, Cremer J, Haneya A. Case report—CARMAT: the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture. Front Cardiovasc Med. 2023;10.
61. Ozbolat IT. Roadmap to Organ Printing. 3D Bioprinting. 2017;243–69.
62. Shanmugam DK, Anitha SC, Souresh V, Madhavan Y, Sampath S, Catakapatri Venugopal D, et al. Current advancements in the development of bionic organs using regenerative medicine and 3D tissue engineering. Materials Technology. 2023;38(1).
63. Bulgin D V., Kovtun AL, Reshetov I V., Radomskaya EY. PROSPECYS FOR FABRICAYION OF ARYIFICIAL HUMAN YISSUES AND ORGANS BASED ON 3D BIOPRINYING. Vestnik Transplantologii i Iskusstvennykh Organov. 2023;25(2):63–81.

64. D'Alessandro AAB, D'Alessandro WB, Herrera SDSC, Mendes SUR, Paiva MJM de, Barbosa Junior OG, et al. The use of Artificial Intelligence and 3D bio-printing for organ transplants. Eyes on Health Sciences V02. 2024 Feb 9;
65. Saroha A, Gupta N. Revolutionizing Surgery: A Review of the Advancements and Challenges in AI and Robotic Surgery. International Conference on Sustainable Computing and Smart Systems, ICSCSS 2023 - Proceedings. 2023;515–23.
66. Cascalho M, Platt JL. New technologies for organ replacement and augmentation. Mayo Clin Proc. 2005;80(3):370–8.
67. Ekhlaspour L, Forlenza GP, Chernavvsky D, Maahs DM, Wadwa RP, Deboer MD, et al. Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system. Pediatr Diabetes. 2019;20(6):759–68.
68. Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct 1;24(10):779–83.
69. Satava RM. Advanced technologies and the future of medicine and surgery. Yonsei Med J. 2008;49(6):873–8.
70. Mithany RH, Aslam S, Abdallah S, Abdelmaseeh M, Gerges F, Mohamed MS, et al. Advancements and Challenges in the Application of Artificial Intelligence in Surgical Arena: A Literature Review. Cureus. 2023 Oct 30;
71. Edgar L, Pu T, Porter B, Aziz JM, La Pointe C, Asthana A, et al. Regenerative medicine, organ bioengineering and transplantation. British Journal of Surgery. 2020 Jun 1;107(7):793–800.
72. LOISANCE D. Mechanical circulatory support systems—future opportunities. European Journal of Cardio-Thoracic Surgery Supplements. 2004 Dec;26(1):S48–53.
73. Slepian M, Alemu Y, Soares J, … RSJ of, 2013 undefined. The SyncardiaTM total artificial heart: in vivo, in vitro, and computational modeling studies. Elsevier [Internet]. [cited 2025 Apr 1]; Available from: https://www.sciencedirect.com/science/article/pii/S0021929012006847
74. Torregrossa G, Morshuis M, … RVA, 2014 undefined. Results with SynCardia total artificial heart beyond 1 year. journals.lww.com [Internet]. [cited 2025 Apr 1]; Available from: https://journals.lww.com/asaiojournal/fulltext/2014/11000/results_with_syncardia_total_artificial_heart.3.aspx
75. Forlenza GP, Ekhlaspour L, Breton M, Maahs DM, Wadwa RP, Deboer M, et al. Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther. 2019 Apr 1;21(4):159–69.
76. Torregrossa G, … AAA of, 2014 undefined. SynCardia: the total artificial heart. pmc.ncbi.nlm.nih.gov [Internet]. [cited 2025 Apr 1]; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4250553/
77. Maynes E, O'Malley T, … JLA of, 2020 undefined. Comparison of SynCardia total artificial heart and HeartWare HVAD biventricular support for management of biventricular heart failure: a systematic review and meta. pmc.ncbi.nlm.nih.gov [Internet]. [cited 2025 Apr 1]; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7160621/
78. Francipane MG, Lagasse E. Toward Organs on Demand: Breakthroughs and Challenges in Models of Organogenesis. Curr Pathobiol Rep. 2016 Sep 1;4(3):77–85.
79. Somasekhar L, Griffiths LG. Current Challenges and Future Promise for Use of Extracellular Matrix Scaffold to Achieve the Whole Organ Tissue Engineering Moonshot. Stem Cells Transl Med. 2023 Sep 1;12(9):588–602.

80. Ravnic DJ, Leberfinger AN, Koduru S V., Hospodiuk M, Moncal KK, Datta P, et al. Transplantation of Bioprinted Tissues and Organs: Technical and Clinical Challenges and Future Perspectives. Ann Surg. 2017;266(1):48–58.
81. Nguyen BTD, Thi HYN, Thi BPN, Kang DK, Kim JF. The roles of membrane technology in artificial organs: Current challenges and perspectives. Membranes (Basel). 2021 Apr 1;11(4).
82. Nalesso F, Garzotto F, Cattarin L, Bettin E, Cacciapuoti M, Silvestre C, et al. The Future for End-Stage Kidney Disease Treatment: Implantable Bioartificial Kidney Challenge. Applied Sciences (Switzerland). 2024 Jan 1;14(2).
83. Mironov V, Kasyanov V, Drake C, Markwald RR. Organ printing: Promises and challenges. Regenerative Med. 2008 Jan;3(1):93–103.
84. Wang X, Yan Y, Zhang R. Recent trends and challenges in complex organ manufacturing. Tissue Eng Part B Rev. 2010;16(2):189–97.
85. Rozga J, Demetriou AA. Artificial Liver Evolution and Future Perspectives. ASAIO Journal. 1995 Oct;41(4):831–7.
86. Buchwald JE, Martins PN. Designer organs: The future of personalized transplantation. Artif Organs. 2022 Feb 1;46(2):180–90.
87. Mitamura Y, Nishida H. Present status and future perspectives of support systems for artificial organs in patients living away from hospital. Journal of Artificial Organs. 2001 Sep;4(3):169–71.
88. Nose Y. The artificial organs program at the Cleveland Clinic Foundation: Past, present, and future. Cleve Clin Q. 1984;51(1):93–104.
89. Peloso A, Dhal A, Zambon JP, Li P, Orlando G, Atala A, et al. Current achievements and future perspectives in whole-organ bioengineering Rocky Tuan; Timothy O'Brien. Stem Cell Res Ther. 2015 Jun 1;6(1).
90. Tatum R, Wong D, Martins PN, Tchantchaleishvili V. Current status and future directions in the development and optimization of thoracic and abdominal artificial organs. Artif Organs. 2023 Mar 1;47(3):451–8.
91. Zhou Q. Building the future of synthetic organ manufacturing and healthcare. Cell Prolif. 2023 May 1;56(5).
92. Hori M. Artificial Liver: Present and Future. Artif Organs. 1986;10(3):211–3.